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the sanctuary sites for human immunodeﬁciency virus (HIV).
HIV replication in the CNS can take an independent course that
leads to the appearance of HIV quasi-species with different
resistance proﬁles [1]. On the other hand, the blood–brain
barrier hinders the delivery of antiretroviral drugs to the pa-
renchyma. Antiretroviral therapy (ART) should thus reach
appropriate levels in CNS. In order to establish this, after
analysis of distributions of antiretroviral drugs into the CNS, a
CNS penetration effectiveness (CPE) score was proposed in
2008 and reviewed in 2010 [2]. Higher CPE scores correlate
with lower central cerebrospinal ﬂuid (CSF) viraemia; a CPE
greater than 6 is thus recommended to achieve control of HIV
replication in the CNS [2]. However, patients with undetect-
able plasma virus load may experience HIV encephalitis.
A 45-year-old white man presented with excessive sleepi-
ness and seizures of 3 months’ duration. Ten years before, the
patient had been diagnosed with acquired immunodeﬁciency
syndrome by a wild-type HIV-1 genotype, with a CD4 nadir of
45 cells/mL. Therapy with lopinavir/ritonavir, abacavir and
lamivudine (CPE 8) had been initiated; virus load had been kept
under control (<20 copies/mL) over follow-up, with occasional
blips, and CD4 count was 700 cells/mL. At admission, he was
afebrile, with normal blood pressure, and neurologic exami-
nation revealed drowsiness, confusion and bilateral Babinski
sign.
During the ﬁrst 24 hours, he manifested generalized tonic-
clonic seizures without recovering consciousness.Clinical Microbiology and Infection © 2015 European Society of CElectroencephalographic studies revealed a left frontoparietal
partial status epilepticus. The patient was transferred to the
intensive care unit, and anticonvulsant treatment was admin-
istered. The CSF showed 20 leukocytes/μL (90% mononuclear
cells), 47 red blood cells/μL, glucose 59 mg/dL and proteins 51
mg/dL. Microbiologic studies (bacterial, fungal and mycobacte-
rial cultures, PCR for herpes simplex virus, cytomegalovirus, JC
virus and varicella zoster virus, luetic serology and crypto-
coccal antigen) were negative. The HIV virus load in the plasma
and the CSF at that time were 56 copies/mL and 28 400 copies/
mL, respectively. Also, discordance of resistance patterns be-
tween CSF and plasma was detected; plasma HIV did not show
any resistance mutation, whereas high-level resistance mutation
to lamivudine and emtricitabine, intermediate resistance to
fosamprenavir, indivavir, lopinavir and neﬁnavir and low-level
resistance to darunavir were detected in CSF. Fig. 1 shows
evolution of virus load and genotype studies. Brain magnetic
resonance imaging (MRI) showed hyperintensity on T2-
weighted images and isointensity on T1-weighted images,
without enhancements, of the periventricular white matter,
corpus callosum, left basal ganglia and middle cerebellar pe-
duncles. ART was modiﬁed according to the resistance studies,
and therapy with darunavir/ritonavir, raltegravir, etravirine,
abacavir and maraviroc (CPE 15) were initiated. After 29-
month follow-up, the patient was completely asymptomatic,
CSF virus load was <20 copies/mL and CNS lesions had
resolved.
Before the introduction of ART, neurologic manifestations
related to HIV were quite common in patients with advanced
HIV infection and were associated with a poor prognosis.
Today, however, although the incidence of neurologic mani-
festations is still high, cases of HIV encephalitis are uncommon
[3]. As in the present case, the majority of patients are men
with long-term HIV infection and low nadir CD4 count (<100
cells/mL). Low CD4 count has been associated with greater
HIV CNS invasion. Patients with higher CSF virus load and
poorer HIV replication control can be more difﬁcult to treat.
Several cases have been reported of differences in virus load
in plasma and CSF. All the described patients had pleocytosis
and HIV replication in CSF. However, a discrepancy in the
pattern of resistance between plasma and CSF strains of HIV,
with wild virus in plasma, as in our patient, has only been
described in four cases [1,3–5]. The CPE score is useful to
establish a suitable combination of drugs with appropriate CNS
penetration. In this case, despite an adequate CPE score (8 at
initial treatment), a strain resistant to the administered ART
appeared. However, the CPE score has some limitations: the
cutoff of 6 has not been validated; it is invalid in patients with
resistance-associated mutations; and it is only available inClin Microbiol Infect 2015; 21: e59–e60
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FIG. 1. Plasma and CSF virus load evolution and genotype studies.
e60 Clinical Microbiology and Infection, Volume 21 Number 8, August 2015 CMIpatients who are receiving more than three drugs. These limi-
tations should be considered before therapy is initiated.
Because of the small number of cases reported, factors
associated with the appearance of new mutations have not been
established. Some authors suggest that it could be related to the
compartmentalization of the CNS, which can cause an inde-
pendent HIV replication. There are also cases of genetic dif-
ferences between virus samples taken from different
compartments of the brain, which may lead to different re-
sponses to treatment according to the characteristics of the
different HIV strains.
As in the present case, all patients had white matter
hyperintensities on MRI [1,3–5]. This radiologic ﬁnding is
important because neurologic manifestations in HIV patients
can be caused by a large variety of toxic, vascular or psychiatric
factors, as well as by drugs. Furthermore, all patients had
marked neurologic and radiologic improvement, as well asClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcontrol of HIV replication in the CNS after optimization of
ART.
In conclusion, HIV encephalitis should not be excluded in
patients with neurologic symptoms, CSF pleocytosis and white
matter hyperintensities on MRI even when plasma virus load is
<20 copies/mL.
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